The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Current progress of siRNA/shRNA therapeutics in clinical trials
Open accessAbstract
Through a mechanism known as RNA interference (RNAi), small interfering RNA (siRNA) molecules can target complementary mRNA strands for degradation, thus specifically inhibiting gene expression. The ability of siRNAs to inhibit gene expression offers a mechanism that can be exploited for novel therapeutics. Indeed, over the past decade, at least 21 siRNA therapeutics have been developed for more than a dozen diseases, including various cancers, viruses, and genetic disorders. Like other biological drugs, RNAi‐based therapeutics often require a delivery vehicle to transport them to the targeted cells. Thus, the clinical advancement of numerous siRNA drugs has relied on the development of siRNA carriers, including biodegradable nanoparticles, lipids, bacteria, and attenuated viruses. Most therapies permit systemic delivery of the siRNA drug, while others use ex vivo delivery by autologous cell therapy. Advancements in bioengineering and nanotechnology have led to improved control of delivery and release of some siRNA therapeutics. Likewise, progress in molecular biology has allowed for improved design of the siRNA molecules. Here, we provide an overview of siRNA therapeutics in clinical trials, including their clinical progress, the challenges they have encountered, and the future they hold in the treatment of human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.275.5307.1787 · Cited by 3,942
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC −/− Colon Carcinoma
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., & Clevers, H. (1997) · Science · doi:10.1126/science.275.5307.1784 · Cited by 2,905
β-catenin is a target for the ubiquitin–proteasome pathway
Aberle, H., Bauer, A., Stappert, J., Kispert, A., & Kemler, R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3797 · Cited by 2,529
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Human ICE/CED-3 Protease Nomenclature
Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., & Yuan, J. (1996) · Cell · doi:10.1016/s0092-8674(00)81334-3 · Cited by 2,372
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
Nordlund, P., & Reichard, P. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142443 · Cited by 1,079
Chromosome Studies on Normal and Leukemic Human Leukocytes
(1960) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/25.1.85 · Cited by 1,069
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J., et al. (2006) · Nature Methods · doi:10.1038/nmeth854 · Cited by 920
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy
Kim, D.-H., Behlke, M. A., Rose, S. D., Chang, M.-S., Choi, S., & Rossi, J. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1051 · Cited by 884
Self-citationWang, L., Miura, M., Bergeron, L., Zhu, H., & Yuan, J. (1994) · Cell · doi:10.1016/s0092-8674(94)90422-7 · Cited by 836
Lane, H. A., & Nigg, E. A. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.6.1701 · Cited by 690
siRNA vs. shRNA: Similarities and differences
Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 660
The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1
Lénárt, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J. J., Hoffmann, M., Rettig, W. J., Kraut, N., & Peters, J.-M. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.046 · Cited by 653
Lopez, P. F., Sippy, B. D., Lambert, H. M., Thach, A. B., & Hinton, D. R. (1998) · Retina · doi:10.1097/00006982-199805000-00035 · Cited by 592
Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801 , Involved in Apoptosis
Shoshani, T., Faerman, A., Mett, I., Zelin, E., Tenne, T., Gorodin, S., Moshel, Y., Elbaz, S., Budanov, A., Chajut, A., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2283-2293.2002 · Cited by 546
Alterations in components of the TGF-β superfamily signaling pathways in human cancer
LEVY, L., & HILL, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.009 · Cited by 539
Caspase-2 Induces Apoptosis by Releasing Proapoptotic Proteins from Mitochondria
Guo, Y., Srinivasula, S. M., Druilhe, A., Fernandes-Alnemri, T., & Alnemri, E. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108029200 · Cited by 521
Ellisen, L. W., Ramsayer, K. D., Johannessen, C. M., Yang, A., Beppu, H., Minda, K., Oliner, J. D., McKeon, F., & Haber, D. A. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00706-2 · Cited by 474
DeVincenzo, J., Lambkin-Williams, R., Wilkinson, T., Cehelsky, J., Nochur, S., Walsh, E., Meyers, R., Gollob, J., & Vaishnaw, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912186107 · Cited by 442
Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral Tolerance
STEINMAN, R. M., HAWIGER, D., LIU, K., BONIFAZ, L., BONNYAY, D., MAHNKE, K., IYODA, T., RAVETCH, J., DHODAPKAR, M., INABA, K., et al. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb06029.x · Cited by 426
Prevalence of Age-Related Maculopathy in Older Europeans: The European Eye Study (EUREYE)
Augood, C. A. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.4.529 · Cited by 390
DiGiusto, D. L., Krishnan, A., Li, L., Li, H., Li, S., Rao, A., Mi, S., Yam, P., Stinson, S., Kalos, M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000931 · Cited by 374
Self-citationTGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells.
Geissmann, F., Revy, P., Régnault, A., Lepelletier, Y., Dy, M., Brousse, N., Amigorena, S., Hermine, O., & Durandy, A. (1999) · PubMed · Cited by 373
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V, Fisch, G., Dames, S., Löffler, K., Fechtner, M., Arnold, W., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302777 · Cited by 368
Hsu, S.-C., Galceran, J., & Grosschedl, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.8.4807 · Cited by 363
TGF-β1 Prevents the Noncognate Maturation of Human Dendritic Langerhans Cells
Geissmann, F., Revy, P., Regnault, A., Lepelletier, Y., Dy, M., Brousse, N., Amigorena, S., Hermine, O., & Durandy, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4567 · Cited by 333
Lopez, P. F., Sippy, B. D., Lambert, H. M., Thach, A. B., & Hinton, D. R. (1996) · PubMed · Cited by 332
Ozaki, H., Yu, A. Y., Della, N. G., Ozaki, K., Luna, J. D., Yamada, H., Hackett, S. F., Okamoto, N., Zack, D. J., Semenza, G. L., et al. (1999) · PubMed · Cited by 323
Functional polarity is introduced by Dicer processing of short substrate RNAs
Rose, S. D. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki732 · Cited by 312
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
Engström, Y., Eriksson, S., Jildevik, I., Skog, S., Thelander, L., & Tribukait, B. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39337-7 · Cited by 285
RNAi‐based therapeutics–current status, challenges and prospects
Tiemann, K., & Rossi, J. J. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900023 · Cited by 283
Self-citationRNAi and small interfering RNAs in human disease therapeutic applications
Lares, M. R., Rossi, J. J., & Ouellet, D. L. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.009 · Cited by 277
Self-citationPlk Is an M-Phase-Specific Protein Kinase and Interacts with a Kinesin-Like Protein, CHO1/MKLP-1
Lee, K. S., Yuan, Y.-L. O., Kuriyama, R., & Erikson, R. L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.7143 · Cited by 268
Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff, C. P., Akkina, R., & Rossi, J. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp185 · Cited by 267
Self-citationFirst-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.273 · Cited by 265
Specific inhibition of bcr-abl gene expression by small interfering RNA
Scherr, M., Battmer, K., Winkler, T., Heidenreich, O., Ganser, A., & Eder, M. (2003) · Blood · doi:10.1182/blood-2002-06-1685 · Cited by 259
DEVINCENZO, J., CEHELSKY, J., ALVAREZ, R., ELBASHIR, S., HARBORTH, J., TOUDJARSKA, I., NECHEV, L., MURUGAIAH, V, VLIET, A., & VAISHNAW, A. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2007.11.009 · Cited by 247
You Wnt some, you lose some: oncogenes in the Wnt signaling pathway
van Es, J. H., Barker, N., & Clevers, H. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00012-6 · Cited by 233
The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling
Vazquez, F., & Sellers, W. R. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00032-3 · Cited by 224
Anterior ischaemic optic neuropathy. I. Terminology and pathogenesis.
Hayreh, S. S. (1974) · British Journal of Ophthalmology · doi:10.1136/bjo.58.12.955 · Cited by 222
TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells.
Takeuchi, M., Alard, P., & Streilein, J. W. (1998) · PubMed · Cited by 220
Bidirectional regulation of macrophage function by TGF-β
Ashcroft, G. S. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00257-9 · Cited by 216
RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus
Zamora, M. R., Budev, M., Rolfe, M., Gottlieb, J., Humar, A., DeVincenzo, J., Vaishnaw, A., Cehelsky, J., Albert, G., Nochur, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201003-0422oc · Cited by 210
Kong, F.-M., Anscher, M. S., Murase, T., Abbott, B. D., Iglehart, J. D., & Jirtle, R. L. (1995) · Annals of Surgery · doi:10.1097/00000658-199508000-00007 · Cited by 201
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas
Krishnan, A., Molina, A., Zaia, J., Smith, D., Vasquez, D., Kogut, N., Falk, P. M., Rosenthal, J., Alvarnas, J., & Forman, S. J. (2005) · Blood · doi:10.1182/blood-2004-04-1532 · Cited by 189
Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades
Weichert, W., Schmidt, M., Gekeler, V., Denkert, C., Stephan, C., Jung, K., Loening, S., Dietel, M., & Kristiansen, G. (2004) · The Prostate · doi:10.1002/pros.20050 · Cited by 188
Friedman, E. D., Gold, L. I., Klimstra, D., Zeng, Z., Winawer, S. J., & Cohen, A. M. (1995) · PubMed · Cited by 182
TGF-β Promotes Immune Deviation by Altering Accessory Signals of Antigen-Presenting Cells
Takeuchi, M., Alard, P., & Streilein, J. W. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.4.1589 · Cited by 161
Necrosis and apoptosis after retinal ischemia: involvement of NMDA-mediated excitotoxicity and p53.
Joo, C., Choi, J., Ko, H. W., Park, K. Y., Sohn, S., Chun, M., Oh, Y. J., & Gwag, B. J. (1999) · PubMed · Cited by 159
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth
Cho, W. G., Albuquerque, R., Kleinman, M. E., Tarallo, V., Greco, A., Nozaki, M., Green, M. G., Baffi, J., Ambati, B. K., Falco, M. D., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812317106 · Cited by 155
Alvarez, R., Elbashir, S. M., Borland, T. D., Toudjarska, I., Hadwiger, P., John, M., Roehl, I., Shulga‐Morskaya, S., Martinello, R., Kahn, J. S., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00014-09 · Cited by 149
RRM1-induced metastasis suppression through PTEN-regulated pathways
Gautam, A., Li, Z.-R., & Bepler, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206232 · Cited by 146
Reagan‐Shaw, S., & Ahmad, N. (2005) · The FASEB Journal · doi:10.1096/fj.04-2910fje · Cited by 138
Single-Nucleotide-Specific siRNA Targeting in a Dominant-Negative Skin Model
Hickerson, R. P., Smith, F. J. D., Reeves, R. E., Contag, C. H., Leake, D., Leachman, S. A., Milstone, L. M., McLean, W. H. I., & Kaspar, R. L. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701060 · Cited by 115
PKN3 is required for malignant prostate cell growth downstream of activated PI 3‐kinase
Leenders, F., Möpert, K., Schmiedeknecht, A., Santel, A., Czauderna, F., Aleku, M., Penschuck, S., Dames, S., Sternberger, M., Röhl, T., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600345 · Cited by 113
PTEN and p53: Who will get the upper hand?
Trotman, L. C., & Pandolfi, P. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00022-9 · Cited by 105
Zhou, B.-S., Tsai, P., Ker, R., Tsai, J., Ho, R., Yu, J., Shih, J., & Yen, Y. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006559901771 · Cited by 104
Incidence of exudative age-related macular degeneration among elderly americans
Javitt, J. C., Zhou, Z., Maguire, M. G., Fine, S. L., & Willke, R. J. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00495-0 · Cited by 102
Fan, H., Huang, A., Villegas, C., & Wright, J. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13181 · Cited by 100
Bai, J., Gorantla, S., Banda, N. K., Cagnon, L., Rossi, J. J., & Akkina, R. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0038 · Cited by 99
Self-citationRosenbaum, D. M., Rosenbaum, P. S., Gupta, H., Singh, M., Aggarwal, A., Hall, D. H., Roth, S., & Kessler, J. A. (1998) · PubMed · Cited by 93
MicroRNA-like off-target transcript regulation by siRNAs is species specific
Burchard, J., Jackson, A. L., Malkov, V. A., Needham, R. H. V., Tan, Y., Bartz, S. R., Dai, H. A., Sachs, A. B., & Linsley, P. S. (2009) · RNA · doi:10.1261/rna.1326809 · Cited by 81
Mechanism of inhibition of LPS-induced IL-12p40 production by IL-10 and TGF-β in ANA-1 cells
Du, C., & Sriram, S. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.64.1.92 · Cited by 78
Eder, I. E., Stenzl, A., Hobisch, A., Cronauer, M. V., Bartsch, G. C., & Klocker, H. (1996) · The Journal of Urology · doi:10.1016/s0022-5347(01)65670-2 · Cited by 76
Koldehoff, M., Steckel, N. K., Beelen, D. W., & Elmaagacli, A. H. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0125-z · Cited by 69
Expression Strategies for Short Hairpin RNA Interference Triggers
Rossi, J. J. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.026 · Cited by 68
Self-citationWatts, J. K., & Corey, D. R. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.109 · Cited by 62
Bu, Y., Yang, Z., Li, Q., & Song, F. (2008) · Oncology · doi:10.1159/000151367 · Cited by 62
Dannull, J., Lesher, D. T., Holzknecht, R. A., Qi, W., Hanna, G., Seigler, H. F., Tyler, D. S., & Pruitt, S. K. (2007) · Blood · doi:10.1182/blood-2007-04-083188 · Cited by 61
Liu, X., Zhou, B., Xue, L., Yen, F., Chu, P. G., Un, F., & Yen, Y. (2007) · Clinical Colorectal Cancer · doi:10.3816/ccc.2007.n.007 · Cited by 59
Jakowlew, S. B., Mathias, A., Chung, P., & Moody, T. W. (1995) · PubMed · Cited by 54
Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes.
Dejneka, N. S., Wan, S., Bond, O. S., Kornbrust, D. J., & Reich, S. J. (2008) · PubMed Central · Cited by 53
Liu, X., Zhou, B., Xue, L., Shih, J., Tye, K. E., Lin, W., Qi, C., Chu, P. G., Un, F., Wen, W. X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0799 · Cited by 52
Maples, P. B., Kumar, P., Yu, Y., Wang, Z., Jay, C. M., Pappen, B. O., Rao, D., Kuhn, J. A., Nemunaitis, J. J., & Senzer, N. N. (2010) · BioProcessing Journal · doi:10.12665/j84.maples · Cited by 32
Tiemann, K., Höhn, B., Ehsani, A., Forman, S. J., Rossi, J. J., & Sætrom, P. (2010) · RNA · doi:10.1261/rna.2005710 · Cited by 24
Self-citationBacterial Delivery of RNAi Effectors: Transkingdom RNAi
Lage, H., & Krühn, A. (2010) · Journal of Visualized Experiments · doi:10.3791/2099 · Cited by 18
Burnett, J., & Rossi, J. J. (2009) · Gene Therapy · doi:10.1038/gt.2009.86 · Cited by 12
Self-citation
Cited by
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Nanochemistry and Nanomedicine for Nanoparticle-based Diagnostics and Therapy
Chen, G., Roy, I., Yang, C., & Prasad, P. N. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00148 · Cited by 1,499
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Metadata
- Authors
- Burnett, J. C., Rossi, J. J., & Tiemann, K.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2011-07-11
- Volume
- 6
- Issue
- 9
- Pages
- 1130-1146
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2008161734
- Cited by
- 444
- References
- 85
- FWCI
- 20.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.